Table 3.
Patients’ disposition based on COVID-19 severity.
| Variable | Severe COVID-19 (n = 151) | Nonsevere COVID-19 (n = 39) | p |
|---|---|---|---|
| Age | |||
| ≥65 years (%) | 112 (74.2) | 17 (43.6) | <0.05 |
| <65 years (%) | 39 (25.8) | 22 (56.4) | |
| Gender | |||
| Male (%) | 98 (64.9) | 28 (71.8) | n.s. |
| Female (%) | 53 (35.1) | 11 (28.2) | |
| Median time between CLL diagnosis and COVID-19 | 88 | 71 | n.s. |
| Treatment for CLL | |||
| Untreated (%) | 64 (42.7) | 9 (23.1) | <0.05 |
| Treated (%) | 86 (57.3) | 30 (76.9) | |
| Treatment during the last 12 months or ongoing | |||
| Yes (%) | 60 (39.7) | 24 (61.5) | <0.05 |
| Untreated or treated > 12 months before (%) | 91 (60.3) | 15 (38.5) | |
| Treatment | |||
| 1 previous line (%) | 48 (31.8) | 14 (35.9) | n.s. |
| 2 or more previous lines (%) | 38 (25.2) | 16 (41.0) | |
| Comorbidities | |||
| >2 | 46 (30.5) | 12 (30.8) | n.s. |
| ≤2 | 105 (69.5) | 27 (69.2) | |
| Hypogammalobulinemia | |||
| Yes | 66 (55.0) | 23 (67.6) | n.s. |
| No | 54 (45.0) | 11 (32.4) | |
| Outcome | |||
| Alive (%) | 96 (63.6) | 37 (97.4) | <0.00001 |
| Dead (%) | 55 (36.4) | 1 (2.6) | |
Bold values indicate statistical significance p < 0.05.